NCT00866333 - A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 13, 2009

Primary Completion Date

February 8, 2013

Study Completion Date

February 8, 2013

Conditions

Hodgkin's Lymphoma

Interventions

DRUG

Entinostat

Entinostat tablets

Trial Locations (6)

Tower Cancer Research Foundation, Beverly Hills

University of Colorado, Denver

Johns Hopkins, Baltimore

University of Nebraska Medical Center, Omaha

Roswell Park Cancer Institute, Buffalo

MD Anderson Cancer Center, Houston